Levorphanol
| Levorphanol | |
|---|---|
| Salts [] | |
|---|---|
| Levorphanol ditartrate | |
| Levorphanol tartrate | |
| Levorphanol hydrochloride | |
| Levorphanol sulfate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 257.37 g/mol [1] |
| Appearance | Crystals [1] |
| Melting point | 198-199 °C [1] |
| Decomposition | When heated to decomp it emits toxic fumes of oxides of nitrogen. [1] |
| Solubility | 1840 mg/L [1] |
| Predicted LogP | 3.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H23NO |
| IUPAC name | (1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol |
| SMILES | CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O |
| InChI | InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1 |
| InChIKey | JAQUASYNZVUNQP-USXIJHARSA-N |
| CAS number | 297-90-5 |
| UNII | 27618J1N2X |
| PubChem CID | 5359272 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 11–16 hours |
| Metabolism | Hepatic |
| Routes of administration | Oral, intravenous, subcutaneous, intramuscular |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - iv: 41 mg/kg - sc: 187 mg/kg - oral: 285 mg/kg Rat: - sc: 110 mg/kg - oral: 150 mg/kg - Oral: 150 mg/kg [1] |
Levorphanol (also known as Levorphan, Aromarone, 17-Methylmorphinan-3-ol, Levorfanol, Levorphanolum, Levorfanolo, Ro 1-5431, (-)-3-Hydroxy-N-methylmorphinan, (-)-N-Methylmorphinan-3-ol or DEA No. 9220) is a substance of the 2-benzylpiperidine class.
Chemistry
Salts []
Levorphanol is typically found in the form of its ditartrate, tartrate, hydrochloride and sulfate salts.
Stereochemistry []
Levorphanol is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Levorphanol matches Lipinski's rule of five.Reagents
There are currently 3 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | yellow-brown | |
| Froehde | no color change |
Pharmacology
MeSH Classification
Mechanism of action []
Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain. [1]
Interactions []
Experience reports
Legal status []
- Australia: Levorphanol is a Schedule 8.
- Brazil: Levorphanol is a A1.[3]
- Canada: Levorphanol is a Schedule I.
- United States: Levorphanol is a Schedule II under the "Controlled Substances Act".
- United Kingdom: Levorphanol is a Class A under the "Misuse of Drugs Act 1971".
- Germany: Levorphanol is a Anlage II under the "Betäubungsmittelgesetz (BtMG)".
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5359272, Levorphanol. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5359272
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Levorphanol. UNII: 27618J1N2X. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/27618J1N2X
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 13:56:04 |
| drugspro | ok | 2026-11-20 13:56:00 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 13:56:00 |
| gsrs | ok | 2026-11-20 13:56:03 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014992) | 2026-11-20 13:56:00 |
| kegg | ok | 2026-11-20 13:56:02 |
| pubchem | ok | 2026-11-20 13:55:59 |
| ok | 2026-11-20 13:56:00 | |
| sider | missing (not in SIDER) | 2026-11-20 13:55:59 |
| structure | ok | 2026-11-20 13:55:59 |
| wikipedia | ok | 2026-11-20 13:56:00 |